Results 101 to 110 of about 6,019 (174)

Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy [PDF]

, 2023
Baumann, Matthias, Baumgartner, Manuela, Behrens, Max, Bernert, Günther, Deschauer, Marcus, Dörnbrack, Katharina, Eisenkölbl, Astrid, Flotats-Bastardas, Marina, Hagenacker, Tim, Hahn, Andreas, Horber, Veronka, Husain, Ralf A., Illsinger, Sabine, Johannsen, Jessika, Kirschner, Janbernd, Köhler, Cornelia, Kölbel, Heike, Lochmüller, Hanns, Müller, Monika, Pechmann, Astrid, Schara-Schmidt, Ulrike, Schimmel, Mareike, Schlachter, Kurt, Schreiber, Gudrun, Schwartz, Oliver, Schwersenz, Inge, Smitka, Martin, Stein, Sabine, Steiner, Elisabeth, Stögmann, Eva, Tassoni, Adrian, Trollmann, Regina, Vill, Katharina, Vogt, Sibylle, von Moers, Arpad, Walter, Maggie C., Weiß, Claudia, Wiegand, Gert, Ziegler, Andreas, Zöller, Daniela   +39 more
core   +1 more source

Pioneering SMA therapies for all types: survival gains, cost dynamics, and performance-based agreements. [PDF]

Cost Eff Resour Alloc
Al-Jedai A, Al-Mudaiheem H, AlSakran A, Bashiri FA, Ghamdi F, Almuhaizea MA, AlSamman A, Awad N, Ojeil R.   +8 more
europepmc   +1 more source

Application of Biomarkers in Spinal Muscular Atrophy. [PDF]

Int J Mol Sci
Gao C, Zhan Y, Chen H, Deng C.
europepmc   +1 more source

CO108 Longitudinal Trends in Hospitalization Rates in Patients with Later-Onset Spinal Muscular Atrophy (SMA) Treated with Nusinersen up to 4.5 Years: Results from the Cherish and Shine Studies

, 2023
Tao Jiang, Basil T. Darras, Bora Youn, C. Makepeace, R. Chin, Z. Berger, Stephanie Raynaud, Angela D. Paradis, Nicole B. Johnson   +8 more
openalex   +1 more source

Biomarkers in spinal muscular atrophy. [PDF]

Front Neurol
Yan L, Zhang J, Zheng J, Hao H.
europepmc   +1 more source

Surgical Access for Intrathecal Therapy in Spinal Muscular Atrophy with Spinal Fusion: Long-Term Outcomes of Lumbar Laminectomy. [PDF]

J Clin Med
Potaczek T, Duda S, Adamczyk J.
europepmc   +1 more source

Quantitative cervical cord MRI in spinal muscular atrophy: a sensitive imaging biomarker of disease evolution and treatment. [PDF]

J Neurol
Asteggiano C, Mazzocchi L, Farina L, Paoletti M, Barzaghi L, Caverzasi E, Parravicini S, Dainesi MI, Gardani A, Savini G, Bergsland N, Ballante E, Wheeler-Kingshott CAMG, Berardinelli A, Pichiecchio A.   +14 more
europepmc   +1 more source

Post-Marketing Safety of Spinal Muscular Atrophy Therapies: Analysis of Spontaneous Adverse Drug Reactions from EudraVigilance. [PDF]

J Clin Med
Belančić A, Mas P, Miletić L, Kovačić Bytyqi B, Vitezić D.   +4 more
europepmc   +1 more source

Enhancing the effects of nusinersen with cybernic treatment using Hybrid Assistive Limb (HAL) in spinal muscular atrophy: a real-world case series and exploratory cohort analysis. [PDF]

Orphanet J Rare Dis
Nakajima T, Saito T, Hashiguchi A, Nakabayashi T, Kodera K, Utsumi K, Kanayama T, Urabe H, Kinoshita S.   +8 more
europepmc   +1 more source

Administration practices of and adherence to nusinersen in children with spinal muscular atrophy: a multicenter disease registry study in China. [PDF]

BMC Pediatr
Peng J, Yao X, Luo R, Wang X, Wu L, Zhong J, Jin R, Lu X, Liang J, Hong S, Yang L, Zhang X, Mao S, Tao Z, Hu J, Sun D, Wang H, Zhang L, Xia Y, Chen K, Wang Y.   +20 more
europepmc   +1 more source